Aurolate Disease Interactions

The use of auranofin and other gold compounds is contraindicated in patients with a history of gold- induced bone marrow aplasia. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy. Hematological warning signs of gold toxicity include a drop in hemoglobin, leukopenia (WBC < 4,000/mm3), granulocytopenia (< 1,500/mm3), and thrombocytopenia (<100,000/mm3).

The use of gold compounds is contraindicated in patients with uncontrolled congestive heart failure. Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.

The use of gold compounds is contraindicated in patients with controlled diabetes mellitus.

The use of gold compounds is contraindicated in patients with hepatic dysfunction. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

The use of gold compounds is contraindicated in patients with urticaria or eczema. Prior to initiation of gold therapy, medical problems that might affect the signs and symptoms used to detect gold toxicity should be under control.

The use of gold compounds is contraindicated in patients with chronic renal failure. These patients may be at increased risk for renal toxicity. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.

The use of gold compounds is contraindicated in patients with severe hypertension. Prior to initiation of gold compounds medical problems that might affect the signs and symptoms used to detect gold compounds toxicity should be under control.

The use of gold compounds is contraindicated in patients with systemic lupus erythematosus. Prior to gold compounds therapy, a complete blood count with a differential, platelet count, urinalysis, and renal and liver function tests should be performed. A complete blood count with a differential, platelet count, and urinalysis should be done at least monthly during therapy.